Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination

Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination

IntroductionDuring the COVID-19 pandemic, certain disease modifying therapies (DMTs) used in multiple sclerosis (MS), such as anti-CD20 therapies, have been associated with decreased humoral responses after SARS-CoV-2 vaccination. Hybrid immunity, referring to immunity after both vaccination and SAR...

Full description

Bibliographic Details
Main Authors: Koos P. J. van Dam, Laura Hogenboom, Eileen W. Stalman, Laura Y. L. Kummer, Maurice Steenhuis, Jim B. D. Keijser, Anja ten Brinke, S. Marieke van Ham, Taco W. Kuijpers, Theo Rispens, Luuk Wieske, Filip Eftimov, Eva M. Strijbis, Joep Killestein, Zoé L. E. van Kempen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
SARS-CoV-2
COVID-19
disease modifying treatment
humoral response
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2022.1032830/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2022.1032830/full

Similar Items